X
Sep 01, 2021 07:46 AM (GMT+8) · EqualOcean
The reporter learned from the relevant person in charge of conbay that in the phase I raised investment project of the company's pharmaceutical base in Jinhua, two production lines of API workshops have been fully produced, and the other four production lines can be put into operation by the end of the year. In 2022, phase II and phase III of the project will be completed and put into operation successively. The company is disposing of all the equity of Guizhou Beite company, which has dragged down the performance in recent two years, and takes "promoting the consistency evaluation of generic drugs" and "secondary development of large brand and large variety products" as the new performance growth point of the company in the future.

This text is a result of machine translation.